(S)-CR8
| Code | Size | Price |
|---|
| AG-CR1-0040-M001 | 1 mg | £50.00 |
Quantity:
| AG-CR1-0040-M005 | 5 mg | £110.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
2-(S)-(1-Ethyl-2-hydroxyethylamino)-6-(4-(2-pyridyl)benzyl)-9-isopropylpurine
Appearance:
White to off-white solid.
CAS:
1084893-56-0
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep under inert gas.Protect from light.
Hazards:
H302
InChi:
InChI=1S/C24H29N7O/c1-4-19(14-32)28-24-29-22(21-23(30-24)31(15-27-21)16(2)3)26-13-17-8-10-18(11-9-17)20-7-5-6-12-25-20/h5-12,15-16,19,32H,4,13-14H2,1-3H3,(H2,26,28,29,30)/t19-/m0/s1
InChiKey:
HOCBJBNQIQQQGT-IBGZPJMESA-N
Long Description:
Chemical. CAS: 1084893-56-0. Formula: C24H29N7O. MW: 431.5. Potent and selective cyclin-dependent kinase (CDK) 1, 2, 5, 7 and 9 inhibitor. Apoptosis inducer. Glycogen synthase kinase (GSK-3alpha/beta) inhibitor.
MDL:
MFCD23160354
Molecular Formula:
C24H29N7O
Molecular Weight:
431.5
Package Type:
Vial
Precautions:
P270, P301, P312, P330
Product Description:
Potent and selective cyclin-dependent kinase (CDK) 1, 2, 5, 7 and 9 inhibitor [1]. Apoptosis inducer [1, 2]. Glycogen synthase kinase (GSK-3alpha/beta) inhibitor [1].
Purity:
>98% (NMR)
Signal word:
Warning
SMILES:
CC[C@@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=C(C=C2)C2=NC=CC=C2)=N1
Solubility Chemicals:
Soluble in DMSO or 100% ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases: K. Bettayeb, et al.; Oncogene 27, 5797 (2008) | CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells: K. Bettayeb, et al.; Genes Cancer 1, 369 (2010) | CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD: N.O. Bukanov, et al.; Cell Cycle 11, 4040 (2012) | Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice: H. Sallam, et al.; BMC Pharmacol. Toxicol. 14, 50 (2013) | Inhibition of NF-kappaB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells: E. Cosimo, et al.; Clin. Cancer Res. 19, 2393 (2013) | Systemic Administration of the Cyclin?Dependent Kinase Inhibitor (S)?CR8 Selectively Reduces Escalated Ethanol Intake in Dependent Rats: S.P. Goulding, et al.; Alcohol Clin. Exp. Res. 43, 2079 (2019)
Related Products
| Product Name | Product Code | Supplier | (R)-Roscovitine | AG-CR1-0006 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (R)-CR8 | AG-CR1-0039 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||